Business
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Net Sales of Orserdu(TM) (elacestrant) and Reiterates Long-Term Cash Receipts Outlook
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Net Sales of Or...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Net Sales of Orserdu™ (elacestrant) and Reiterates Long-Term Cash Receipts Outlook\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Patent-protected exclusivity and uncapped deal structure offers attractive return profile –\n \n \n \n \n – Acquisition generates substantial near-term cash flows and long-term portfolio growth –\n \n \n \n \n – DRI Healthcare expects flat to slightly growing cash receipts through 2030 –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n June 30, 2023\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the \"Trust\"), a global leader in providing financing to advance innovation in the life sciences industry, has purchased a royalty interest in the worldwide net sales of Orserdu™ from Eisai Co., Ltd. (\"Eisai\") for\n \n US$85 million\n \n . This transaction brings DRI Healthcare's total deployments since its IPO in\n \n February 2021\n \n to\n \n US$570 million\n \n , with an additional\n \n US$55 million\n \n in potential milestones and options.\n \n \n \n \n \n \n \n \n \n Orserdu™ is an oral, selective estrogen receptor degrader (\"SERD\") discovered by Eisai and marketed by Stemline Therapeutics, Inc., a subsidiary of the Menarini Group. It is the first and only approved targeted therapy used in the treatment of postmenopausal women or adult men with ESR1-mutated ER+/HER2- metastatic breast cancer, who have experienced disease progression despite prior endocrine therapy. Orserdu™ was approved by the U.S. Food and Drug Administration in\n \n January 2023\n \n and is under review by the European Medicines Agency for potential approval.\n \n \n \"Orserdu™ provides a safe, effective, and convenient treatment for patients that have progressed on initial therapy,\" said\n \n Behzad Khosrowshahi\n \n , Chief Executive Officer of the Trust. \"This transaction provides a tangible e...